Ravulizumab Demonstrates Significant Ability to Reduce Relapses in NMOSD
Over a median of 73.5 weeks of follow-up time, zero adjudicated relapses were observed for those with AQP4+ NMOSD on ravulizumab.
After initial findings were
Ravulizumab, a long-acting C5 compliment inhibitor, was well-tolerated among patients with aquaporin-4 antibody-positive (AQP4+NMOSD) and significantly lowered the risk of relapse and Hauser Ambulation Index (HAI) worsening. Ravulizumab was originally FDA-approved in 2018 to treat adults with paroxysmal nocturnal hemoglobinuria and was later expanded to include children and adolescents in 2021. Weeks before the original results from CHAMPION-NMOSD were announced, the agent received FDA greenlight to treat generalized myasthenia gravis.
Led by
The primary end point of time to first adjudicated on-trial relapse was met in the ravulizumab arm, as zero relapses were observed over 84.01 patient-years (PY) of treatment. In comparison, there were 20 adjudicated relapses in the placebo arms over 46.93 PY of treatment, representing a 98.6% relapse risk reduction (RRR) with ravulizumab. At 48 weeks, 100% of the patients on ravulizumab were relapse free compared with 63% of those on placebo.
"NMOSD relapses are unpredictable and often cause permanent disability, including blindness, paralysis and even premature death. Our data build on the established role of complement inhibition in managing NMOSD and reinforce our commitment to patient-centered innovation,” Marc Dunoyer, chief executive officer, Alexion, said in a statement.3 "Results from the CHAMPION-NMOSD trial highlight the potential for ULTOMIRIS to substantially reduce the risk of relapse and ease treatment burden for the community."
In CHAMPION-NMOSD, the median follow-up time was 73.5 weeks for ravulizumab and 36.0 weeks for placebo. At the conclusion of the trial, the ARR of 0.00 with ravulizumab was superior to both the predefined comparator ARR of 0.25 and the placebo ARR of 0.42 (95% CI, 0.27-0.66; P <.0001). Additionally, only 3.4% of patients on ravulizumab experienced clinically important worsening in HAI score compared with 23.4% of those on placebo (odds ratio [OR], 0.16; 95% CI, 0.03-0.77; P = .023).
Similar to what was reported in May, the safety profile of ravulizumab was consistent with previous studies. In the ravulizumab and placebo groups, 93.1% and 95.7% of patients, respectively, experienced at least 1 treatment-emergent adverse event (TEAE). Serious AEs were less frequent in the active drug group, with only 13.8% reported compared with 55.3% in the placebo arm. There were no deaths in the study, and 2 vaccinated patients in the ravulizumab group reported meningococcal infections; however, both recovered with no sequelae and 1 continued in the trial.
REFERENCES
1. Pittock SJ, Barnett M, Bennett LJ, et al. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial. Presented at: ECTRIMS Congress 2022; October 26-28; Amsterdam, Netherlands. Abstract O051.
2. Ultomiris met primary end point in CHAMPION-NMOSD phase 3 trial in adults with neuromyeltis optica spectrum disorder. News release. AstraZeneca. May 5, 2022. Accessed October 25, 2022. https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-nmosd-ph-iii-trial-met-primary-endpoint.html
3. Alexion aims to advance NMOSD treatment landscape with exceptional Ultomiris (ravulizumab-cwvz) efficacy data at ECTRIMS 2022. News release. AstraZeneca. October 12, 2022. Accessed October 25, 2022. https://www.astrazeneca-us.com/media/press-releases/2022/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-efficacy-data-at-ectrims-2022.html
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
